Library Item Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Do dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of joint pain?

Posted by on Sep 21, 2017 in Diabetes mellitus | 0 comments

In a nutshell  This study compared data from clinical trials investigating if dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with a greater risk of arthralgia (joint pain) in type 2 diabetes patients. They found there was slight increased risk for developing arthralgia in patients taking DPP-4 inhibitors. Some background Managing...

Read More

Does dapagliflozin reduce the risk of cardiovascular complications in patients with type 2 diabetes?

Posted by on Sep 21, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study investigated if dapagliflozin reduces the risk of developing cardiovascular complications in patients with type 2 diabetes. They found that dapagliflozin was associated with a lower risk of non-fatal heart attack and stroke compared to dipeptidyl peptidase-4 inhibitors (DPP-4i). Some background Cardiovascular (CV, heart...

Read More

Durvalumab improves time to disease progression in previously treatment non-small cell lung cancer

Posted by on Sep 21, 2017 in Lung cancer | 0 comments

In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...

Read More

Adding mitoxantrone to oral FCR (fludarabine, cyclophosphamide & rituximab) does not improve treatment response

Posted by on Sep 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined whether adding mitoxantrone (Novantrone) to the treatment combination known as FCR improves outcomes for chronic lymphocytic leukemia (CLL). Researchers reported no significant benefit when mitoxantrone was added to FCR. Some background For physically fit CLL patients, the chemotherapy and immunotherapy...

Read More

Pembrolizumab in patients with chronic lymphocytic leukemia with Richter’s transformation

Posted by on Sep 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of pembrolizumab in the treatment of chronic lymphocytic leukemia that has undergone Richter’s transformation. This study concluded that patients with Richter’s transformation responded to pembrolizumab.  Some background Chronic lymphocytic leukemia is a cancer where...

Read More

Treatment outcomes in 477 patients with blast-phase CML

Posted by on Sep 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined treatment outcomes in patients with blast-phase chronic myeloid leukemia (CML). Authors reported that intensive treatment early followed by stem cell transplantation remains as the most effective approach. Certain patient characteristics and treatment history are significant predictors of outcomes.  Some...

Read More

Preventing fungal infections after chemotherapy in acute leukemia patients

Posted by on Sep 14, 2017 in Leukemia | 0 comments

In a nutshell The aim of this study was to examine the effect of preventative fungal treatment in acute leukemia patients with different risk factors. Researchers identified a number of risk factors that can increase the incidence of a severe fungal infection after chemotherapy. Preventative fungal treatment for patients undergoing primary chemotherapy...

Read More

Inotuzmab ozogamicin as a treatment option for patients with acute lymphoblastic leukaemia.

Posted by on Sep 14, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if inotuzumab ozogamicin (Besponsa) is a more effective treatment than the standard therapy for relapsed acute lymphoblastic leukemia. This study concluded that inotuzumab ozogamicin is a more effective treatment than standard therapy for relapsed acute lymphoblastic leukemia.   Some background...

Read More